Xencor shares are trading higher after the company announced four new XmAb programs in development for the treatment of patients with autoimmune diseases and provided updates from dose-escalation studies evaluating its first-in-class oncology programs.
Portfolio Pulse from Benzinga Newsdesk
Xencor shares rise as the company announces four new XmAb programs for autoimmune diseases and updates on its oncology programs.
September 09, 2024 | 3:26 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Xencor's stock is trading higher following the announcement of four new XmAb programs targeting autoimmune diseases and updates on oncology program studies.
The announcement of new programs and updates on existing studies is likely to boost investor confidence, leading to a positive impact on Xencor's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100